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The CH2( C H3 for IgM and IgE) domain of an antibody plays
an important role in mediating effector functions and
preserving antibody stability. It is the only domain in human
immunoglobulins (Igs) which is involved in weak interchain
protein–protein interactions with another CH2 domain solely
through sugar moieties. The N-linked glycosylation at Asn297
is conserved in mammalian IgGs as well as in homologous
regions of other antibody isotypes. To examine the structural
details of the CH2 domain in the absence of glycosylation and
other antibody domains, the crystal structure of an isolated
unglycosylated antibody  1C H2 domain was determined at
1.7 A ˚ resolution and compared with corresponding CH2
structures from intact Fc, IgG and Fc receptor complexes.
Furthermore, the oligomeric state of the protein in solution
was studied using size-exclusion chromatography. The results
suggested that the unglycosylated human antibody CH2
domain is a monomer and that its structure is similar to that
found in the intact Fc,IgG and Fc receptor complex structures.
However, certain structural variations were observed in the Fc
receptor-binding sites. Owing to its small size, stability and
non-immunogenic Ig template, the CH2-domain structure
could be useful for the development by protein design of
antibody domains exerting effector functions and/or antigen
speciﬁcity and as a robust scaffold in protein-engineering
applications.
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Accepted 5 August 2008
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CH2 domain, 3dj9, r3dj9sf.
1. Introduction
Antibodies, also called immunoglobulins (Igs), comprise two
identical light chains and heavy chains linked by disulﬁde
bonds. The light chain contains a variable (VL) domain and a
constant (CL) domain. The heavy chain has four to ﬁve
domains, depending on the isotype, including a variable (VH)
domain and several constant (CH) domains: three CH domains
in IgG, IgA and IgD and four CH domains in IgM and IgE. The
antigen-binding fragment (Fab) consists of the light chain (VL
and CL) and the ﬁrst two domains of the heavy chain (VH and
CH1) and is speciﬁcally involved in antigen binding. The Ig Fc
(fragment crystallizable) portion consists of two constant
domains, namely CH2 and CH3, from each heavy chain and
binds to effector molecules in order to elicit host responses.
CH2 is the only antibody domain that exhibits very weak
carbohydrate-mediated interchain protein–protein inter-
actions, in contrast to the extensive interactions that occur
between VH–VL,C L–CH1a n dC H3–CH3 domains as seen inintact antibody structures. The crystal structures of intact IgG
(Larson et al., 1991; Harris et al., 1992, 1998; Saphire et al.,
2001) and Fc (Krapp et al., 2003) reveal that the CH2 domain
interacts with the other CH2 domain through sugar moieties
only. The N-linked glycosylation at Asn297 of the CH2 domain
is conserved in all mammalian IgG molecules and the homo-
logous regions of IgM, IgD and IgE. From a functional point
of view, the CH2 domain contains large portions of the entire
binding sites for complement and Fc receptors that are critical
for the effector function of antibodies (Vidarsson & van de
Winkel, 1998; Woof & Burton, 2004) as well as for binding to
the neonatal Fc receptor (Martin et al., 2001), which is
important for the preservation of antibody stability. The
isolation and characterization of a CH2 domain from myeloma
IgG was reported quite early on as this domain is involved in
complement activity (Seon & Pressman, 1975). Previously, a
series of amino-acid substitutions in the
CH2 domains of various IgG subclasses
was carried out to enhance the differ-
ential afﬁnity for the Fc receptor
(Canﬁeld & Morrison, 1991). In the
crystal structures of IgG1 Fc–Fc III
receptor complexes, Fc receptor (Fc R)
exclusively interacts through the CH2
domains of IgG1 Fc, in which the
binding site includes the Asn297 residue
of the CH2 domain (Sondermann et al.,
2000; Radaev et al., 2001). Several
recent studies have also been focused
on the characterization of the antibody
constant domains, CH2 and CH3, in
order to understand the folding and
stability mechanisms of these domains
(Demarest et al., 2004; Feige et al., 2004;
McAuley et al., 2008). Of these, kinetic
studies exploring the folding mechanism
of the CH2 domain suggested that an
unglycosylated murine CH2 domain is a
monomer with relatively low stability
(Feige et al., 2004). Although several
crystal structures are available of intact
IgG (Larson et al., 1991; Harris et al.,
1992, 1998; Saphire et al., 2001), Fc
(Krapp et al., 2003; Matsumiya et al.,
2007), Fab fragments (Stanﬁeld et al.,
2006) and variable antibody domains
VH or VL (Dottorini et al., 2004; Park et
al., 2008), there are no structures of the
CH2 domain. Such a structure would
allow us to determine the structural
details in the absence of glycosylation
and other antibody domains. Here, we
present the crystal structure of an
isolated unglycosylated CH2 antibody
domain. The isolated CH2 domain is a
monomer and is similar to the CH2-
domain structures embedded in the
intact Fc, IgG and Fc receptor complex
despite the absence of extensive inter-
actions with sugar moieties and its
isolation from other antibody domains.
However, certain differences do exist
which could be important in the use of
such domains as scaffolds for high-
afﬁnity binders.
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Figure 1
Structure of the CH2 antibody domain and structural comparison with the corresponding region in
the Fc and IgG structures. (a) Ribbon diagram of the isolated unglycosylated CH2 domain from IgG
 1 is shown with a gradient ramp of colors according to the temperature factors (B factors): blue for
lower ( 11 A ˚ 2), green for medium ( 23 A ˚ 2) and red for higher ( 48 A ˚ 2) values. The N- and
C-termini as well as strands A–G are marked. (b) The isolated CH2 domain (green) was
superimposed with a least-squares algorithm using the C
  traces of the CH2 domains of fucosylated
(blue; PDB code 2dtq) and nonfucosylated (purple; PDB code 2dts) Fc structures. (c) Superposition
of the isolated CH2 structure (green) with that of CH2 portions of an intact IgG (PDB code 1hzh)
using the C
 -trace alignment. The heavy and light chains of IgG are shown in red and blue,
respectively. The carbohydrate moieties between the CH2 domains of the Fc and IgG structures in
(b) and (c) are omitted for clarity.High-afﬁnity binders based on variable domains (also
termed domain antibodies; dAbs; Holt et al., 2003) have
attracted much attention in recent years owing to their small
size and stability, which are suitable for targeting the sterically
conﬁned binding sites on antigens or other protein surfaces.
Since the unglycosylated antibody CH2 domain appears to be a
stable monomer and to be structurally independent, it might
be useful as an alternative to domain antibodies for the
generation of high-afﬁnity binders. Therefore, the structure
may be useful for optimization of the antibody CH2-domain
stability, creation of alternative antibody scaffolds based on
the CH2 domain (nanoantibodies) and as a small structural
scaffold in protein design. Also, the use of CH2 as a scaffold is
much easier and cost-effective if expressed in bacteria that do
not support glycosylation.
2. Materials and methods
2.1. Cloning, protein expression and purification
The gene encoding the CH2 antibody domain was obtained
by PCR ampliﬁcation using the cDNA of the MAK33  1 heavy
chain as a template. Protein preparation and puriﬁcation were
carried out as previously described (Zhang et al., 2004).
2.2. Size-exclusion chromatography
Puriﬁed CH2 was loaded onto a Superdex75 10/300 GL
column that had been pre-equilibrated with phosphate-
buffered saline (PBS). The protein was eluted with PBS at
0.5 ml min
 1. The Superdex75 column was calibrated with
protein molecular-weight standards of 669.0, 440.0, 232.0,
158.0, 67.0, 44.0, 25.0 and 13.7 kDa.
2.3. Crystallization, data collection and structure
determination
High-throughput screening of crystallization conditions was
carried out with a Hydra II Plus crystallization robot (Matrix
Technologies, Hudson, New Hampshire, USA) using the
Crystal Screen kit from Hampton Research (Laguna Niguel,
California, USA). Thin plate-shaped crystals were grown from
a crystallization condition consisting of 30% PEG 1500 with
equal volumes of protein and well solutions. The crystals were
cryoprotected with the well solution after 25% glycerol had
been introduced. The diffraction data were collected on the
SER-CAT 22-ID beamline of the Advanced Photon Source
(APS), Argonne National Laboratory. Data were processed
and scaled with the HKL-2000 program suite (Otwinowski &
Minor, 1997). Data-collection statistics are given in Table 1.
The structure of the CH2 antibody domain was solved by
molecular replacement with the CCP4 version of AMoRe
(Navaza, 2001) using the CH2-domain structure extracted
from the intact antibody IgG b12 structure (Saphire et al.,
2001; PDB code 1hzh) as a search model. The initial model
obtained from molecular replacement was iteratively reﬁned
using CNS (Bru ¨nger et al., 1997) and rebuilt with Coot
(Emsley & Cowtan, 2004) and O (Jones et al., 1991). Water
molecules were added automatically using CNS followed by
visual inspection and reﬁnement. The reﬁnement statistics are
presented in Table 1. Figures were prepared with PyMOL
(DeLano, 2002).
3. Results and discussion
3.1. Structure of the isolated unglycosylated CH2 domain
We used recombinant DNA techniques to express the CH2
domain of an antibody (IgG) in Escherichia coli and puriﬁed
the protein, which resulted in the production of the isolated
unglycosylated CH2 domain with a molecular weight of
12 kDa. Crystals appeared in 30% PEG 1500 within a week
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Table 1
X-ray data-collection and reﬁnement statistics for the antibody CH2
domain.
Data collection
Wavelength (A ˚ )1 . 0
Space group P21
Unit-cell parameters (A ˚ ,  ) a = 36.14, b = 40.68,
c = 39.13,   = 106.7
Resolution range (A ˚ ) 26.36–1.75 (1.82–1.75)
Observations 42457
Unique reﬂections 10493
Redundancy 4.0 (3.0)
Completeness (%) 94.4 (72.0)
I/ (I) 27.2 (7.0)
Rmerge† (%) 0.040 (0.129)
Reﬁnement statistics
R factor‡ (%) 20.1 (23.6)
Rfree‡ (%) 22.7 (31.1)
No. of atoms: protein/water 866/111
R.m.s.d. bond distances (A ˚ ) 0.006
R.m.s.d. bond angles ( )1 . 4
Wilson B value (A ˚ 2) 17.0
Average B values (A ˚ 2)
Protein atoms 20.8
Water O atoms 28.7
Ramachandran plot
Most favored ’ and   angles (%) 95.7
Additional allowed ’ and   angles (%) 4.3
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.‡ R factor and Rfree = P   jFobsj j Fcalcj
   =
P
jFobsj, where Rfree was calculated over 5% of the amplitudes
chosen at random and not used in the reﬁnement.
Figure 2
A sample of puriﬁed CH2 was analyzed on Superdex75 10/300 GL column
calibrated with molecular-weight standards. The arrows indicate the
positions where the 43.0, 25.0 and 13.7 kDa molecular-weight standards
eluted.and grew as large plates that were suitable
for X-ray diffraction. The crystal structure
of the CH2 domain was determined at 1.7 A ˚
resolution by molecular replacement using
the glycosylated CH2 domain from the
structure of an intact antibody IgG b12
determined previously at 2.7 A ˚ resolution
(Saphire et al., 2001). A summary of X-ray
data-collection and reﬁnement statistics is
presented in Table 1. The asymmetric unit
contained one CH2 domain and the ﬁnal
model included a total of 107 amino-acid
residues, with more than 95% of residues in
the most favored region of the Ramachan-
dran plot (Ramachandran & Sasisekharan,
1968). A ribbon diagram of the unglycosyl-
ated CH2 antibody domain is shown in
Fig. 1(a), with a color coding corresponding
to the B-factor values: blue for lower
( 11 A ˚ 2), green for medium ( 23 A ˚ 2) and
red for higher ( 48 A ˚ 2) values. The overall
structure is similar to the intact glycosylated
CH2 domain as found in the Fc and IgG
antibody structures (Figs. 1b and 1c),
displaying a stable immunoglobulin fold
with minor differences in the loop regions,
the termini and the orientations of side
chains of the binding site or surface-exposed
residues. No signiﬁcant intermolecular
interactions that warrant the consideration
of oligomerization are observed in the
crystal lattice, which is in agreement with
our size-exclusion chromatography data
suggesting that the protein exists as a mono-
mer in solution (Fig. 2). Our current data
combined with the previous results from
thermodynamic studies on the CH2 domain
of an IgG antibody (Feige et al., 2004) have
conﬁrmed that the isolated unglycosylated
research papers
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Figure 3
Stereoviews showing structural comparisons
between the isolated CH2 domain and similar CH2
regions in Fc receptor complexes. (a)C
 -trace
superposition of the isolated CH2 domain (green)
and the CH2 domains of Fc RIII–Fc complex
structures in various crystal forms: hexagonal forms
(PDB codes 1e4k and 1t89, in blue and orange,
respectively) and an orthorhombic form (PDB code
1t83, magenta). The Fc RIII receptor molecules in
the complexes are shown in red. Arrows point to the
Fc receptor-binding sites of the CH2 domains. The
carbohydrate moieties between the CH2 domains of
the Fc RIII–Fc complexes are omitted for clarity.
(b) A close-up view of one of the binding sites from
the D/E loop of the CH2 domain, highlighting the
orientation of the Tyr296 residue. (c) A close-up
view of another binding site from the F/G loop of
the CH2 domain is shown. Amino-acid side chains
are labeled according to the orthorhombic structure
(PDB code 1t83).CH2 domain is a stable monomer in the absence of glycosyl-
ation and other antibody domains.
3.2. Structural comparisons of the CH2 domain with intact
Fc, IgG and Fc receptor complex structures
To analyze the conformational features of the isolated CH2
domain, we compared it with recent crystal structures of
human IgG Fc fragments with and without a fucose residue
attached to the sugar moieties at Asn297 (Matsumiya et al.,
2007; PDB codes 2dts and 2dtq), intact IgG b12 (Saphire et al.,
2001; PDB code 1hzh) and Fc receptor complexes (Sonder-
mann et al., 2000; Radaev et al., 2001; PDB codes 1e4k, 1t83
and 1t89). The two CH2 domains in these antibody structures
interact with each other through sugar moieties. Superposition
of the unglycosylated CH2 domain on the corresponding CH2
domains of Fc and IgG yielded root-mean-square deviations
(r.m.s.d.s) of 0.5 and 0.6 A ˚ , respectively (Figs. 1b and 1c). This
clearly indicates that glycan removal as well as isolation of the
domain does not affect the structural integrity of the mono-
meric CH2 antibody domain. Furthermore, we superimposed
the CH2 antibody domain with the CH2 regions of Fc RIII–Fc
complex structures available in three different crystal forms
and found that the r.m.s.d.s ranged from 0.5 to 1.0 A ˚ (Fig. 3a).
In all three reported Fc RIII–Fc complexes, the D/E loop
(residues 296–299 between  -strands D and E) of the CH2
domain in Fc directly makes critical intermolecular inter-
actions with the Fc RIII receptor. However, in the ortho-
rhombic form only (PDB code 1t83), Tyr296 of the D/E loop in
the CH2 protrudes out at the tip and makes contacts with
Lys128 and Asp129 of Fc RIII (in magenta; Fig. 3b). In the
two hexagonal forms of the Fc RIII–Fc complexes, Tyr296 in
the D/E loop has a different conformation (blue and orange in
Fig. 3b), which suggests a requirement for conformational
ﬂexibility of Tyr296 for the binding of CH2t oF c  RIII. When
we overlaid the isolated CH2 domain on these complex
structures (in green; Fig. 3b), we observed that Tyr296 of the
isolated CH2 domain exhibited an upright conformation with
the hydroxyphenyl side chain pointing out of the D/E loop at
the tip as found in the Fc receptor complex structure of the
orthorhombic form. The other CH2 domain of Fc region in the
complex also makes interactions with the Fc RIII receptor
through its F/G loop (residues 325–331 between  -strands F
and G), where Pro329 of the CH2 domain is sandwiched by
Trp90 and Trp113 of the receptor, which is also observed in the
orthorhombic structure (Fig. 3c). This Fc receptor-binding site
on the CH2 domain is structurally well conserved, in contrast
to the other binding site where Tyr296 of the D/E loop exhibits
signiﬁcant conformational ﬂexibility. From these structural
analyses, we found that the isolated unglycosylated CH2
domain has a similar conformation to that embedded in the
intact Fc and IgG structures. However, a signiﬁcant variation
was noted in the Fc receptor-binding sites when compared
with the Fc RIII–Fc complexes, particularly at residue Tyr296
of the CH2 domain.
Isolated antibody fragments can be used as scaffolds for
binders. The smallest functional antigen-binding fragment of
an antibody, avariable domain, eitherVH or VL,hasbeen used
successfully. From the structural point of view, the major
difference between the variable and constant domains is the
connecting loops between the  -strands. The comple-
mentarity-determining region (CDR) loops in the variable
domains that make contacts with the antigen are longer than
those found in the constant domains which interact with
effector molecules. Using the structural details together with
in vitro phage-display selection (Weiss & Penner, 2008;
Dimitrov & Marks, 2008) and computational protein-loop
design (Hu et al., 2007), the CH2 domain could be engineered
to have predetermined speciﬁcities for various antigens and
proteins. In general, the Ig fold is shared by many evolution-
arily unrelated or distantly related proteins (Halaby et al.,
1999). A DALI database search (Holm & Sander, 1998) using
the CH2-domain fragment resulted in more than 470 different
protein structures with a Z score greater than 2, mainly of
immune-system and cell-adhesion molecules. Therefore, the
scope for protein design using the antibody CH2-domain
template may have wider applications in addition to thera-
peutic high-afﬁnity binders and stable structural scaffolds.
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